Team

Dan Fero

Dan is a Managing Director with OMX Ventures. Dan brings over 16 years of experience in venture capital investing, life science strategy consulting, and biomedical research to the OMX team. Prior to OMX, Dan was a Principal with Mérieux Equity Partners where he led over $30M in direct investments into therapeutics and life science tools companies. Dan has also spent 5 years with L.E.K. Consulting conducting life science corporate strategy and M&A advisory work, and 3 years as a professional political operative on various Congressional campaigns around the U.S.

Education: PhD in Biomedical Sciences from the University of California, San Diego, and a BA in Biology from Rhode Island College

Linkedin ↗

Nick Haft

Nick is a Managing Director with OMX Ventures. Prior to OMX, Nick was the sole managing partner at Arcos Ventures, where he deployed over $80M of capital into 20+ bio-related companies. Some of Nick’s prior investments include Finch Therapeutics, Pendulum Therapeutics, Ginkgo Bioworks, 10X Genomics, Imagen, Compass Pathways and many others. Nick also co-founded Delix Therapeutics, a startup focused on developing breakthrough therapies for psychiatric and neurological disorders.

Education: Bachelor of Science in Economics, Wharton School, University of Pennsylvania

Linkedin ↗

Craig Asher

Craig is a Managing Director with OMX Ventures. Prior to OMX, Craig managed a multi-family office where he led investments in 20+ early-stage startups in bio-tools, biotech, cyber security and specialty technology. Four of those investments are now valued at over $1B. Craig has served as a Director or Board Observer for many transformational companies, including Twist Bioscience (NASDAQ: TWST) and QuantaLife (NASDAQ: BIO). In a past life, Craig was a software product manager at 3 exited startups.

Education: AB from Stanford University with distinction and Phi Beta Kappa; MBA from Northwestern University Kellogg; MS in industrial engineering from Northwestern University. Pursuing MS in biotechnology degree at Johns Hopkins University

Linkedin ↗

Paul Conley

Paul is a Venture Partner with OMX Ventures. Paul has been leading investments in science-based start-ups since 2007 through roles at previous funds - Paladin Capital and Vertical Venture Partners. With OMX and General Inception he leverages his broad technology background, real world research experience, and over a decade of prior founder/CEO operating experience to partner with scientific founders in building commercial companies from scratch. Paul has served as Director or Board Observer at more than 25 companies to date, including 10X Genomics (NASDAQ: TXG), Twist Bioscience (NASDAQ: TWST), Inscripta and QuantaLife (NASDAQ: BIO).

Education: PhD Applied Mechanics/Engineering Science, MS Bioengineering UC San Diego (UCSD), MS Mech/Aero Engineering, BS Mech University of Virginia (UVA)

Linkedin ↗

Jamie Kasuboski

Jamie is a Vice President with OMX Ventures. Prior to OMX Jamie developed deep experience in early-stage Biotech investing and company creation while working on the investment team at RA Capital. In that role he served on the board of Enara Bio, Avilar Therapeutics, and Endor Therapeutics. Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics.

Education: PhD in Molecular and Cellular Biology from the University of Notre Dame and a BS in Biology with a minor in Chemistry from Hillsdale College

Linkedin ↗

Swetha Murali

Swetha is a Senior Associate with OMX Ventures. Prior to OMX, Swetha was an Associate at Flagship Pioneering after completing the Fellows Program in 2018. In this role, she co-founded and operated three new companies in AI/deep learning, agriculture, and cell therapy. Before joining Flagship, she was a postdoctoral fellow at Boston Children’s Hospital / Harvard Medical School developing novel cures for hearing and balance disorders.

Education: PhD in Medicine (Neuropharmacology) from the University of Sydney and Bachelor of Biomedical Science from the University of Newcastle

Linkedin ↗

Rob Plasschaert

Rob is a Scientist in Residence with OMX Ventures. Prior to OMX, Rob was the Associate Director CNS gene therapy at AVROBIO, a public gene therapy company focused on rare disorders. Rob managed a team of bench scientists and led the development of several internally initiated programs up to IND filing. Prior to his role at AVROBIO, Rob was a postdoctoral fellow at the Whitehead Institute where he worked with Rudolf Jaenisch, a pioneer in stem cell models of human disease. Rob’s NIH-funded research focused on the genetic and epigenetic underpinnings of common and rare forms of neurodegeneration.

Education: PhD in Cell & Molecular Biology from the University of Pennsylvania and Bachelors of Science from the University of Notre Dame

Linkedin ↗

Fred Sweeney

Fred is a Venture Partner with OMX Ventures. He has extensive experience in the healthcare industry with senior leadership roles leading strategy and corporate development in both small and large organizations. Prior to OMX, Fred was Chief Business Officer of MeMed Diagnostics Ltd, an Israel/Boston-based disruptive commercial stage technology company and had responsibility for Corporate Strategy and Corporate Development. During his tenure, the company executed several high value partnerships, and raised an additional $90M of equity financing. Prior to joining MeMed, Fred held leadership positions at Versant Ventures, Northern Biologics, bioMérieux and T2 Biosystems. He also currently serves as an Independent Director on the Board of QVella Corporation and CTRL Therapeutics and holds an Adjunct Professor position at the University of Toronto, faculty of Medicine, where he teaches a graduate level course on entrepreneurship in life sciences.

Education: PhD in Molecular and Medical Genetics from the University of Toronto and Bachelors of Science from McGill University

Linkedin ↗